Flow cytometric determination of DNA ploidy in gynecologic cancer has made progress due to the development of sample treatment procedures and special initiatives by the Japan Cytometry Society in standardizing the determination of DNA ploidy in solid cancers. Although a strategy for the clinical application of DNA ploidy in gynecologic cancer has not yet been formulated, it is expected that DNA ploidy studies would serve to elucidate cell-biological features of gynecologic cancer and provide an entrance to the study of analytical cytology.
